Press Releases

04.12.2022

Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated with Endometriosis

04.11.2022

Pfizer Names David M. Denton Chief Financial Officer

04.07.2022

Pfizer to Acquire ReViral and Its Respiratory Syncytial Virus Therapeutic Candidates

03.29.2022

Pfizer and BioNTech Receive Expanded U.S. Emergency Use Authorization for an Additional COVID-19 Vaccine Booster in Individuals Aged 50 Years and Older

03.29.2022

Pfizer Announces Positive Top-line Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis, Underscoring Best-in-Class Potential

03.24.2022

Pfizer Granted FDA Breakthrough Therapy Designation for Respiratory Syncytial Virus Vaccine Candidate for the Prevention of RSV in Older Adults

03.23.2022

Pfizer Announces Positive Top-Line Results for Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients

03.22.2022

Pfizer Invites Public to View and Listen to Webcast of May 3 Conference Call with Analysts

03.22.2022

Pfizer to Supply UNICEF up to 4 Million Treatment Courses of Novel COVID-19 Oral Treatment for Low- and Middle-Income Countries

03.11.2022

Pfizer Completes Acquisition of Arena Pharmaceuticals

03.09.2022

Pfizer Initiates Phase 2/3 Study of Novel COVID-19 Oral Treatment in Pediatric Participants

03.08.2022

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference